Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -37.50%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.19 per share when it actually produced a loss of $0.15, delivering a surprise of 21.05%.Over the last four qua ...